Abstract: Metastatic castration-resistant prostate cancer (mCRPC) represents the terminal stage of prostate cancer. When this stage is reached, the prognosis is poor, and there are limited therapeutic options. However, in recent years, poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a novel class of targeted agents that demonstrate significant efficacy against mCRPC, especially in patients harboring homologous recombination repair (HRR) gene mutations, such as BRCA1/2. The China Anti-Cancer Association Genitourinary Tumor Professional Committee convened multidisciplinary experts to standardize the clinical use of PARPs based on real-world clinical experience and evidence-based medicine. This committee systematically reviewed the mechanism of action, indicators, genetic testing strategies, therapeutic regimens, and the adverse event management of PARP inhibitors. In addition, it has provided recommendations for the use of PARP in specific populations, including elderly patients and those with hepatic or renal impairment. In particular, it has emphasized the importance of individualized treatment. The goal is to provide clinicians with standardized guidance, promote precision therapy for mCRPC, and enhance patient prognosis and quality of life.